Explore the surprising rise of Chinese short dramas produced in Hollywood. Discover how these fast-paced series are reshaping the American film industry.The Scale of the Phenomenon:Approximately 100 Chinese short drama productions starting monthly in LA.Film students heavily involved in various production roles.Behind the Scenes: Production & Logistics:Fast-paced 7-9 day shoots, location accessibility, and detailed "run downs."Labor practices: 12-hour turnaround, overtime, and high script output (10+ episodes daily).Content, Audience, and the "爽" (Shuang) Factor:Dramatic genres: CEO power plays, revenge plots ("dog-blood" & "爽剧").Audience differences: Men in China vs. women (20-40) in the US.The appeal of "爽": Fast-paced, dramatic, and illogical storylines.The Talent Pool:"Top-tier" short drama actors with constant bookings.Experienced Hollywood actors from shows like "Grey's Anatomy."Actor motivations: Craft practice, visibility, and new opportunities.Salaries: $700-$2000 per day, based on data-driven popularity and Chinese investor preferences.The Role of Hollywood and Chinese Investment:Primarily Chinese funding and control over content and casting.Limited Hollywood creative input.Leveraging Hollywood's infrastructure: locations, equipment, and crew.Challenges and Future Perspectives:Limited US investment and understanding of the short drama formula.Director aspirations beyond short dramas.Sustainability tied to data and viewership on Chinese-funded apps.Key Takeaways: A cultural and filmmaking collision fueled by Chinese investment. Fast-paced narratives catering to a global audience. Opportunities for Hollywood talent and crew. Creative control and content direction influenced by Chinese preferences.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
SpaceX Said to Pursue 2026 IPO
10 Dec 2025
Bloomberg Tech
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
Japan Claims AGI, Pentagon Adopts Gemini, and MIT Designs New Medicines
10 Dec 2025
The Daily AI Show
Eric Larsen on the emergence and potential of AI in healthcare
10 Dec 2025
McKinsey on Healthcare
What it will take for AI to scale (energy, compute, talent)
10 Dec 2025
Azeem Azhar's Exponential View
Reducing Burnout and Boosting Revenue in ASCs
10 Dec 2025
Becker’s Healthcare -- Spine and Orthopedic Podcast